Zenas Biopharma Inc Dossier - Source-backed chat

Zenas Biopharma Inc

ZBIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.36

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $26.97Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.8B

Enterprise Value $1.6B

Shares Outstanding 62.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Zenas BioPharma (ZBIO) represents a highly compelling clinical-stage immunology play with a de-risked lead asset, obexelimab, which recently met its primary and key secondary endpoints in the registrational Phase 3 INDIGO trial for IgG4-Related Disease (IgG4-RD). With a BLA submitted to the FDA in Q2 2026 and an MAA submission planned for the EMA in H2 2026, ZBIO is on the cusp of transitioning into a commercial-stage biopharmaceutical company. The company's balance sheet is exceptionally strong, boasting $718.5 million in cash, cash equivalents, and investments as of March 31, 2026, following successful concurrent equity and convertible debt offerings. This capital extends the company's cash runway into 2029, fully funding the potential commercial launch of obexelimab and the continued development of its broader pipeline, including orelabrutinib in Multiple Sclerosis and ZB021 in early-stage clinical development.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$32.00

Mean target$47.00

High · most bullish analyst$59.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$32.0015%

Regulatory delays or a Complete Response Letter (CRL) from the FDA regarding the obexelimab BLA, or safety/efficacy disappointments in the Phase 2 SLE trial or early-stage pipeline. High cash burn continues without near-term commercial revenue, causing the stock to decline toward the street-low target of $22.00.

Base CaseCentral scenario

$47.0060%

Matches the consensus mean

Standard regulatory approval of obexelimab in IgG4-RD by mid-2027, followed by a steady commercial rollout. Phase 2 SLE data in Q4 2026 is supportive of further development, and early-stage pipeline assets progress on track. The stock moves toward the consensus Wall Street price target of approximately $44.00, reflecting a successful transition to a commercial-stage company.

Bull CaseUpside scenario

$59.0025%

Rapid FDA and EMA approval of obexelimab in IgG4-RD with a highly successful commercial launch, capturing a dominant share of the multi-billion-dollar IgG4-RD market. Positive Phase 2 SunStone data in SLE in Q4 2026 triggers a lucrative global co-development partnership, while orelabrutinib and ZB021 deliver outstanding clinical readouts, driving the stock toward the high-end analyst target of $55.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked lead asset (obexelimab) with highly statistically significant Phase 3 INDIGO trial data in IgG4-RD, showing a 56% reduction in flare risk.
Robust balance sheet with $718.5 million in cash, cash equivalents, and investments, providing a runway into 2029.
Differentiated, non-depleting mechanism of action (co-engaging CD19 and FcγRIIb) with convenient subcutaneous self-administration.
Strong institutional backing and experienced leadership team with a proven track record in drug development and commercialization.

Key Investment Risks

Regulatory risks associated with the FDA's review of the newly submitted BLA for obexelimab.
Commercial execution risks as a first-time launching company in a niche, rare disease market.
Clinical trial risks for ongoing mid-to-late-stage programs, including orelabrutinib in MS and obexelimab in SLE.
Potential dilution from future equity raises or conversion of the $200 million convertible senior notes due 2032.

Thesis Invalidation Triggers

FDA issuance of a Complete Response Letter (CRL) or significant delay in the approval of obexelimab for IgG4-RD.
Failure of the Phase 2 SunStone trial in SLE to meet its primary efficacy endpoints in Q4 2026.
Unanticipated safety signals or severe adverse events emerging in the ongoing clinical trials of obexelimab or orelabrutinib.
Significant acceleration in cash burn rate that shortens the projected cash runway to under 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.